Bellerophon Therapeutics News

Bellerophon Therapeutics | 15-12G: Notice of termination of registration of a class of securities under Section 12(g) (and amendment thereto)

Mar 7 00:34

Bellerophon Therapeutics | 8-K: Current report

Mar 5 06:55

Bellerophon Therapeutics | SCHEDULE 13G: Others

Mar 1 23:09

Bellerophon Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Perceptive Advisors LLC(0.0%),Joseph Edelman(0.0%), etc.

Feb 15 05:55

Bellerophon Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-TANG CAPITAL PARTNERS, LP(0.0%),Tang Capital Management, LLC(0.0%), etc.

Feb 15 05:03

Bellerophon Therapeutics | DEFA14A: Others

Feb 13 04:50

Bellerophon Therapeutics | DEFA14A: Others

Feb 13 01:40

Bellerophon Therapeutics | 8-K: Current report

Jan 30 22:32

Bellerophon Therapeutics | SCHEDULE 13G: Others

Jan 27 03:35

Bellerophon Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-507 Summit LLC(8.4%),Lepercq Capital Management LLC(8.4%), etc.

Jan 26 23:49

Bellerophon Therapeutics | 8-K: Current report

Jan 22 13:00

Bellerophon Therapeutics | 8-K: Current report

Jan 10 13:00

Bellerophon Therapeutics | DEFA14A: Others

Jan 3 13:00

Bellerophon Therapeutics | 25-NSE: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)

Dec 27, 2023 13:00

Bellerophon Therapeutics | 8-K: Current report

Dec 13, 2023 05:10

Bellerophon Therapeutics | 8-K: Current report

Nov 22, 2023 05:05

Bellerophon Therapeutics: Q3 2023 Earnings Report

Nov 15, 2023 05:31

Bellerophon Therapeutics | DEF 14A: Definitive information statements

Nov 7, 2023 05:30

Bellerophon Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Oct 27, 2023 22:50

Bellerophon Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Theodore Wang(0.5%),Puissance Life Science Opportunities Fund VI(0%), etc.

Oct 18, 2023 09:05